SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : DBOT - Demegen, Inc.
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10PreviousNext  
To: jmhollen who started this subject11/10/2002 2:36:51 PM
From: jmhollen   of 4
 
Company Highlights:

Demegen’s drugs are proprietary synthetic and natural peptides (small proteins). Antecedents for these compounds occur in nature as part of the immune system of animals, insects and plants. These new drugs are a powerful new tool to combat bacterial and fungal infections, sexually transmitted diseases and cancer. Generally, the peptides bind to and kill harmful microorganisms and cancer cells.

Demegen’s drugs destroy pathogens that are resistant to existing antibiotics and antifungals. Resistance is becoming a major health problem.

One of the drugs has already been safely administered to over 400 patients.

The Cystic Fibrosis Foundation awarded Demegen $1.5 million for development of a therapy to treat Pseudomonas infections in CF subjects, and a second award to identify a new molecule for B. cepacia.

Funding support for its vaginal microbicide is being provided by the National Institutes of Health.

P113D, the drug for CF, has been awarded Orphan Drug designation by the FDA.

Funding support for the CF product is expected from a large biotechnology company.

Demegen’s peptides also have extensive applications for combating important fungal and bacterial crop diseases and Demegen controls key patents for this use of antimicrobial peptides. Working with USDA and university collaborators, proofs of concept have been shown in several crops.

Outlook:

The Company plans to effect licenses or partnerships that will fund and develop its lead molecules for specific applications.

.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News